Properties of adaptive clinical trial signature design in the presence of gene and gene-treatment interaction

References

• Benjamini, Y., Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), 57(1):289–300.
   Google Scholar
• Bickel, P. J., Levina, E. (2004). Some theory for Fisher's linear discriminant function, ‘Naive Bayes’, and some alternatives when there are many more variables than observations. Bernoulli, 10(6):989–1010.
   Google Scholar
• Bishop, C. (2006). Pattern Recognition and Machine Learning. New York: Springer.
   Google Scholar
• Cambon, A., Baumgartner, K., Brock, G., Cooper, N., Wu, D., Rai, S. (2015a). Classification of clinical outcomes using high-throughput informatics: Part 1-nonparametric method reviews. Model Assisted Statistics and Applications 10:3–23.
   Google Scholar
• Cambon, A. C., Baumgartner, K. B., Brock, G. N., Cooper, N. G. F., Rai, S. N., Wu, D. (2015b). Classification of clinical outcomes using high-throughput informatics: Part 2-parametric method reviews. Model Assisted Statistics and Applications, ( In Press).
   Google Scholar
• CDER guidance for industry: qualification process for drug development tools. (2014). Retrieved March 25, 2015, from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat-ion/Guidances/UCM230597.pdf
   Google Scholar
• Dancey, J. E., Freidlin, B. (2003). Targeting epidermal growth factor receptor – are we missing the mark? Lancet 362(9377):62–64.
   Google Scholar
• Dempster, A. P., Laird, N. M., Rubin, D. B. (1977). Maximum Likelihood from Incomplete Data via the EM Algorithm. Journal of the Royal Statistical Society. Series B (Methodological), 39(1):1–38. doi: 10.2307/2984875.
   Google Scholar
• Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., …Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45(2):228–247. doi: https://doi.org/10.1016/j.ejca.2008.10.026.
   Google Scholar
• Freidlin, B., Jiang, W., Simon, R. (2010). The cross-validated adaptive signature design. Clinical Cancer Research 16(2):691–698. doi: 10.1158/1078-0432.ccr-09-1357.
   Google Scholar
• Freidlin, B., Korn, E. L., Gray, R. (2013). Marker sequential test (MaST) design. Clinical Trials 11(1):19–27. doi: 10.1177/1740774513503739.
   Google Scholar
• Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11(21):7872–7878. doi: 10.1158/1078-0432.ccr-05-0605.
   Google Scholar
• Gu, X., Yin, G., Lee, J. J. (2013). Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemporary Clinical Trials 36(2):642–650. doi: https://doi.org/10.1016/j.cct.2013.09.009.
   Google Scholar
• Guidance for Industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. (2012, December). Retrieved March 25, 2015, from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan-ces/UCM230597.pdf.
   Google Scholar
• Hastie, T., Tibshirani, R., Friedman, J. (2009). The Elements of Statistical Learning (2nd ed). New York: Springer.
   Google Scholar
• Hudis, C. A. (2007). Trastuzumab-mechanism of action and use in clinical practice. New England Journal of Medicine 357(1):39–51. doi: 10.1056/NEJMra043186.
   Google Scholar
• Irvin, W. J. Jr., Carey, L. A. (2008). What is triple-negative breast cancer? European Journal of Cancer, 44(18):2799–2805. doi: https://doi.org/10.1016/j.ejca.2008.09.034.
   Google Scholar
• LaVange, L. M. (2014). The role of statistics in regulatory decision making. Therapeutic Innovation & Regulatory Science 48(1):10–19. doi: 10.1177/2168479013514418.
   Google Scholar
• Lu, W., Zhang, H. H., Zeng, D. (2013). Variable selection for optimal treatment decision. Statistical Methods in Medical Research 22(5):493–504. doi: 10.1177/0962280211428383.
   Google Scholar
• Rothmann, M. D., Zhang, J. J., Lu, L., Fleming, T. R. (2012). Testing in a prespecified subgroup and the intent-to-treat population. Drug Information Journal 46(2):175–179. doi: 10.1177/0092861512436579.
   Google Scholar
• Saenger, Y. M., Wolchok, D. D. (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immunity 8(1):1–7.
   Google Scholar
• Scher, H. I., Nasso, S. F., Rubin, E. H., Simon, R. (2011). Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clinical Cancer Research 17(21):6634–6640. doi: 10.1158/1078-0432.ccr-11-1105.
   Google Scholar
• Sheather, S. J., Jones, M. C. (1991). A reliable data-based bandwidth selection method for kernel density estimation. Journal of the Royal Statistical Society. Series B (Methodological) 53(3):683–690. doi: 10.2307/2345597.
   Google Scholar
• Simon, R. (2013). Genomic Clinical Trials and Predictive Medicine. New York: Cambridge University Press.
   Google Scholar
• Sridhara, R., Mandrekar, S. J., Dodd, L. E. (2013). Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clinical Cancer Research 19(10):2613–2620. doi: 10.1158/1078-0432.ccr-12-2938.
   Google Scholar
• Tibshirani, R. (1996). Regression shrinkage and selection via the Lasso. Journal of the Royal Statistical Society. Series B (Methodological) 58(1):267–288.
   Google Scholar
• Venables, W. N., Ripley, B. D. (2002). Modern Applied Statistics with S (4th ed). New York: Springer.
   Google Scholar
• Xu, P., Brock, G. N., Parrish, R. S. (2009). Modified linear discriminant analysis approaches for classification of high-dimensional microarray data. Computational Statistics & Data Analysis 53(5):1674–1687. doi: https://doi.org/10.1016/j.csda.2008.02.005.
   Google Scholar